Magic mushrooms are due to the return of aging in mice – can they do the same for humans?

A newly published study in The aging partner of nature in magazines He explains that Psilocin, which is a secondary result of the consumption of silosipine, the active ingredient in the narcotic mushrooms, extends the cells of cellular cells for human skin and lung cells with more than 50 %.

In parallel, the researchers also conducted the first term in the long term in vain Study the evaluation of the systemic effects of the cellosibin spice in the elderly mice for 19 months, or the equivalent of 60-65 years of humans. The results indicated that the mice that got a preliminary low dose of cellosipine of 5 mg, followed by a high monthly dose of 15 mg for 10 months, was a 30 % increase in survival compared to the mice that did not receive any. These mice also offered more healthy physical features, such as improved fur, less white hair and hair regression.

While traditionally searched for mental health benefits, this study indicates that Psilocybin affects the multiple features of aging by reducing oxidative stress, improving DNA repair responses, and maintaining the length of telomere. Telomarat are the structural ends of the chromosome, and protecting it from damage that may lead to the formation of age -related diseases, such as cancer, nervous degeneration, or cardiovascular diseases. These founding processes affect human aging and the beginning of these chronic diseases.

The study concluded that Psilocybin may have the ability to revolutionize anti -aging treatments and could be an effective intervention in the population.

“Most cells in the body express serotonin receptors, and this study opens new boundaries of how cylosipine affects systemic aging, especially when they are managed later in life,” says Louise Hacker, a doctorate, a doctorate, and this study opens new boundaries for how cylosipine affects systemic aging operations, especially when they are managed later in life, “where research and financing began.

While many of what selenibin seeks to the brain, few studies have studied its systemic effects. Psilocybin connects with hallucinogenic effects, but the majority of cells in the body express serotonin receptors.

“Our study opens new questions about what long -term treatments can do. In addition, even when late intervention begins in mice, it continues to improve survival, and is clinically related to healthy aging,” Hacker adds, a co -professor at the Paylor College of Medicine.

This news comes in the wake of the last KFF report that the average age of the United States is still less than other countries similar to income and size, with an average age of 78.4 years, compared to 82.5 years in elsewhere. It was not only the minimum, but with an increase in the lifetime of similar countries by 7.9 years from 1980-2022, while the average age in the United States has increased only 4.7 years.

“This study provides strong pre -clinical evidence that cylospine may contribute to healthy aging – not only longer, but a better kind of life in subsequent years,” says the director of narcotic research in the Department of Psychiatry, Ali John Zarrabi, PhD in medicine. “As a doctor in the field of tilted care, one of my biggest fears is to prolong life at the expense of dignity and function. But these mice were not alive for a longer period-I witnessed better aging,” added Zarrabi, who is participating in the study.

Zarrabi stressed the importance of more research among the elderly, as well as the well -documented overlap between physical and mental health.

“Emuri actively participates in the clinical trials of the second and third stage of treatment with the help of celosipine depression, and these results indicate that we also need to understand the systematic effects of the cellosipine program in aging groups,” said Zarrabi. “My hope is that if the treatment is approved with the help of celosipine as a depression intervention by the FDA in 2027, then getting a better quality of life would translate into a longer and healthier life.”

Study began at Emory University and funded by many awards, including the IMAGINE, Sental and Impact (i3), Faculty of Medicine at Imori University; Georgia CTSA NIH Award; A grant from the Emory’s Woodruff Health Sciences Center in Age.